Results 51 to 60 of about 1,044,683 (223)

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).

, 2022
Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC)
Anne Maree Woollett (13622302), Ian Collins (13064952), Susan Bowles (5279852), David M Ashley (11461396), Sujata Patil (674937), Conrad Brandt (13622290), Theresa M Hayes (13622311), Sally E Baron-Hay (13622299), Mustafa Khasraw (13078896), Shu Fen Wong (13622320), Violet Rudo Mukaro (13622284), Linda West (6335345), Michelle Edwards (343232), Alexander David Guminski (13622314), Inger Olesen (13074450), Gregory Mitchell (836801), Kimberley Prince (13622308), Jacinta Bryan (13622317), Robert Spokes (13622305)   +18 more
core  

ZMIZ2–DUX4–LGR5 Signaling Axis Maintains Stemness Properties and Facilitates Docetaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study identifies ZMIZ2 as a therapeutic target for docetaxel‐resistant triple‐negative breast cancer, sustaining cancer stemness‐associated properties and docetaxel resistance. ZMIZ2 upregulation enhances DUX4‐mediated LGR5 activation through the SWI/SNF components BRG1 and BAF57.
Xueting Gan, Shulei Sun, Ran Hu, Yuheng Feng, Xinhao Wu, Fangqi Liu, Xuyong Lin, Xiupeng Zhang, Xuezhu Rong, Qiang Han   +9 more
wiley   +1 more source

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.

, 2016
Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast ...
Karen White (2275696), Caitlin Clare Murphy (13622296), Ian Collins (13064952), David M Ashley (11461396), Sujata Patil (674937), Conrad Brandt (13622290), Sally E Baron-Hay (13622299), Mustafa Khasraw (6335354), Violet Rudo Mukaro (13622284), Elisabeth Rippy (13622287), Linda West (6335345), Robert Tobler (13622293)   +11 more
core   +1 more source

Efficacy and safety of nab-paclitaxel in advanced or recurrent small cell lung cancer: a single-arm meta-analysis

Frontiers in Pharmacology
BackgroundAlthough various effective agents used as second- and third-line treatments for advanced or recurrent small cell lung cancer have improved overall survival, the optimal therapeutic regimen remains controversial. Previous studies have shown that
Jun-Chen Liu, Hong-Jing Yu, Zhi Chen, Qi Deng   +3 more
doaj   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?

, 2013
Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic ...
Amalia Luce, Lucia Fiorillo, Pierfrancesco Tassone, Iole Cucinotto, Mariamena Arbitrio, Pierosandro Tagliaferri, Nicoletta Staropoli, DomenicoCiliberto, Simona Gualtieri, Anna Grimaldi, Michele Caraglia   +10 more
core   +2 more sources

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice [PDF]

, 2013
Design: Pharmacokinetic and pharmacodynamic parameters of cremophor-paclitaxel, nab-paclitaxel (human-albumin-bound paclitaxel, Abraxane) and a novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel) were evaluated in genetically engineered mouse models (
Jodrell, D. I., Neesse, A., Tuveson, D. A., Frese, K. K., Chan, D. S., Richards, F. M., Bapiro, T. E., Ellenrieder, V., Howat, W. J.   +8 more
core   +2 more sources

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source

Quality and value-focused albumin-bound paclitaxel decision support for pancreatic, lung, and breast cancer in southeastern United States.

, 2014
246 Background: Albumin-bound paclitaxel is FDA approved as single agent for breast cancer, in combination with carboplatin for non-small cell lung cancer (NSCLC), and with gemcitabine for pancreatic cancer.
William S. Shimp, Anna E. Schorer, Anmol Baranwal, Avinash Mamgain, Charles L. Bennett, Melissa Armitage, Jurgen Kogler, Laura Rose Bobolts, Dinah Faith Q. Huff, Sharon Davis, William J. Hrushesky, Marc L. Fishman   +11 more
core   +1 more source